Chemotherapy-induced Nausea and Vomiting (CINV) can be defined as acute CINV, delayed CINV or anticipatory CINV.
Antiemetic guideline consistency and incidence of
chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study.
Initial control of
chemotherapy-induced nausea and vomiting in patient quality of life.
(5.) Baker PD, Morzorati SL, Ellet ML: The pathophysiology of
chemotherapy-induced nausea and vomiting. Gastroenterol Nurs 2005; 28: 469-480
-
Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Granisetron transdermal system (Sancuso[R]) is the first transdermal medication indicated for use in
chemotherapy-induced nausea and vomiting. In her article in the December 2009 issue of the Clinical Journal of Oncology Nursing, Schulmeister describes the nursing and patient considerations for use of transdermal delivery of granisetron.
About
Chemotherapy-Induced Nausea and Vomiting (CINV) CINV is estimated to affect 85% of cancer patients undergoing chemotherapy and can result in a delay or discontinuation of chemotherapy treatments.
Under Rosen's previous leadership, the company said it has grown from a late-stage, clinical company with one programme in development into a revenue-generating, commercial organisation with fast-growing
chemotherapy-induced nausea and vomiting (CINV) and postoperative pain management franchises.